Basel Medical Group Reshapes Board with New Director Appointment

Basel Medical Group Ltd ( (BMGL) ) has provided an announcement.

Basel Medical Group Ltd, a Singapore-based healthcare company listed on Nasdaq as a foreign private issuer, operates from Gleneagles Medical Centre and complies with U.S. reporting requirements under Form 20-F. Its presence on the U.S. market underscores its ambition to access international capital while maintaining its operational base in Asia.

On March 30, 2026, Basel Medical Group Ltd reported that its board appointed Chief Commercial Officer Tan Boon Chye (Darren) as a director, replacing director Jianing Lu, who resigned from the board the same day. Lu remains the company’s Chief Financial Officer, signaling a targeted reshuffle of board responsibilities rather than a broader management change, which may modestly adjust governance dynamics while preserving financial leadership continuity.

More about Basel Medical Group Ltd

Basel Medical Group Ltd, listed on Nasdaq under the ticker BMGL, is a Singapore-based healthcare company operating out of the Gleneagles Medical Centre. The company functions as a foreign private issuer in the U.S. capital markets and files its reports with the Securities and Exchange Commission under Form 20-F.

Average Trading Volume: 42,555

Technical Sentiment Signal: Strong Sell

Current Market Cap: $10.09M

For an in-depth examination of BMGL stock, go to TipRanks’ Overview page.